OA19179A - Use of probiotics in the treatment and/or prevention of atopic dermatitis. - Google Patents
Use of probiotics in the treatment and/or prevention of atopic dermatitis. Download PDFInfo
- Publication number
- OA19179A OA19179A OA1201900019 OA19179A OA 19179 A OA19179 A OA 19179A OA 1201900019 OA1201900019 OA 1201900019 OA 19179 A OA19179 A OA 19179A
- Authority
- OA
- OAPI
- Prior art keywords
- probiotic composition
- treatment
- composition according
- lactis
- longum
- Prior art date
Links
- 230000000529 probiotic Effects 0.000 title claims abstract description 108
- 239000006041 probiotic Substances 0.000 title claims abstract description 108
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 108
- 206010012438 Dermatitis atopic Diseases 0.000 title abstract description 3
- 201000008937 atopic dermatitis Diseases 0.000 title abstract description 3
- 230000002265 prevention Effects 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 167
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 44
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 44
- 240000004403 Lactobacillus casei Species 0.000 claims abstract description 43
- 229940009291 Bifidobacterium longum Drugs 0.000 claims abstract description 5
- 229940017800 Lactobacillus casei Drugs 0.000 claims abstract description 5
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 5
- 201000004624 dermatitis Diseases 0.000 claims description 67
- 206010003645 Atopy Diseases 0.000 claims description 59
- 231100000406 dermatitis Toxicity 0.000 claims description 58
- 244000005700 microbiome Species 0.000 claims description 32
- 235000013305 food Nutrition 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 235000016709 nutrition Nutrition 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 229940079593 drugs Drugs 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 235000013618 yogurt Nutrition 0.000 claims description 7
- 210000004080 Milk Anatomy 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- -1 sachets Substances 0.000 claims description 6
- 235000015140 cultured milk Nutrition 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 235000013339 cereals Nutrition 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 235000013350 formula milk Nutrition 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 241000131482 Bifidobacterium sp. Species 0.000 claims description 3
- 241000170280 Kluyveromyces sp. Species 0.000 claims description 3
- 241000186610 Lactobacillus sp. Species 0.000 claims description 3
- 241000194022 Streptococcus sp. Species 0.000 claims description 3
- 235000015173 baked goods and baking mixes Nutrition 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 235000013351 cheese Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000015243 ice cream Nutrition 0.000 claims description 3
- 241000235088 Saccharomyces sp. Species 0.000 claims description 2
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000015203 fruit juice Nutrition 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000015192 vegetable juice Nutrition 0.000 claims description 2
- 229940112822 Chewing Gum Drugs 0.000 claims 1
- 241001134770 Bifidobacterium animalis Species 0.000 abstract description 2
- 229940118852 Bifidobacterium animalis Drugs 0.000 abstract description 2
- 239000000902 placebo Substances 0.000 description 52
- 229940068196 placebo Drugs 0.000 description 52
- 239000003246 corticosteroid Substances 0.000 description 27
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 19
- 229960001334 Corticosteroids Drugs 0.000 description 19
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 19
- 201000010099 disease Diseases 0.000 description 17
- 230000000699 topical Effects 0.000 description 17
- 230000001387 anti-histamine Effects 0.000 description 16
- 239000000739 antihistaminic agent Substances 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 13
- 208000003251 Pruritus Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 208000005679 Eczema Diseases 0.000 description 9
- 230000001580 bacterial Effects 0.000 description 9
- 231100001003 eczema Toxicity 0.000 description 9
- 230000001575 pathological Effects 0.000 description 9
- 231100000494 adverse effect Toxicity 0.000 description 8
- 230000001684 chronic Effects 0.000 description 8
- 230000002757 inflammatory Effects 0.000 description 8
- 241000186000 Bifidobacterium Species 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000001965 increased Effects 0.000 description 7
- 230000000813 microbial Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241000606125 Bacteroides Species 0.000 description 6
- 241000605861 Prevotella Species 0.000 description 6
- 241000192031 Ruminococcus Species 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000003491 Skin Anatomy 0.000 description 5
- 208000006641 Skin Disease Diseases 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000002393 scratching Effects 0.000 description 5
- 238000006748 scratching Methods 0.000 description 5
- 241001608234 Faecalibacterium Species 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 238000000585 Mann–Whitney U test Methods 0.000 description 4
- 241000736262 Microbiota Species 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 4
- 230000001154 acute Effects 0.000 description 4
- 230000002146 bilateral Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 101700072192 ent1 Proteins 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000002459 sustained Effects 0.000 description 4
- 208000006673 Asthma Diseases 0.000 description 3
- 229940046731 Calcineurin inhibitors Drugs 0.000 description 3
- 210000002421 Cell Wall Anatomy 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 210000003608 Feces Anatomy 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 206010022114 Injury Diseases 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 229940039696 Lactobacillus Drugs 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- KASDHRXLYQOAKZ-XDSKOBMDSA-N Pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 3
- 229960001967 Tacrolimus Drugs 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 229940029983 VITAMINS Drugs 0.000 description 3
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 3
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 230000002354 daily Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000002068 genetic Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229960005330 pimecrolimus Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001823 pruritic Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamins Natural products 0.000 description 3
- 229920001670 16S ribosomal RNA Polymers 0.000 description 2
- 241001156739 Actinobacteria <phylum> Species 0.000 description 2
- 241001430332 Bifidobacteriaceae Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- YNNUSGIPVFPVBX-NHCUHLMSSA-N Clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 2
- 210000004443 Dendritic Cells Anatomy 0.000 description 2
- SOYKEARSMXGVTM-HNNXBMFYSA-N Dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 2
- 229960004597 Dexfenfluramine Drugs 0.000 description 2
- 206010049796 Excoriation Diseases 0.000 description 2
- 208000004526 Exfoliative Dermatitis Diseases 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N Hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N Loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
- 229960003088 Loratadine Drugs 0.000 description 2
- 210000004698 Lymphocytes Anatomy 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 206010039083 Rhinitis Diseases 0.000 description 2
- 206010040867 Skin hypertrophy Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 229960001803 cetirizine Drugs 0.000 description 2
- 229960002881 clemastine Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229960001882 dexchlorpheniramine Drugs 0.000 description 2
- 230000000378 dietary Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N ethyl[(2S)-1-[3-(trifluoromethyl)phenyl]propan-2-yl]amine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 235000020932 food allergy Nutrition 0.000 description 2
- 229960000930 hydroxyzine Drugs 0.000 description 2
- 230000035874 hyperreactivity Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N levocetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 230000002906 microbiologic Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000016046 other dairy product Nutrition 0.000 description 2
- 230000001991 pathophysiological Effects 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108020004465 16S Ribosomal RNA Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000701474 Alistipes Species 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 1
- 229940009289 Bifidobacterium lactis Drugs 0.000 description 1
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 208000002352 Blister Diseases 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N Cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 206010011655 Cushingoid Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N Deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010012456 Dermatitis exfoliative generalised Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 210000003979 Eosinophils Anatomy 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016766 Flatulence Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 229960004675 Fusidic Acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N Fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 1
- 206010020864 Hypertrichosis Diseases 0.000 description 1
- 206010020863 Hypertrichosis Diseases 0.000 description 1
- 206010074052 Hypothalamic pituitary adrenal axis suppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241001468155 Lactobacillaceae Species 0.000 description 1
- 241001112724 Lactobacillales Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241001468191 Lactobacillus kefiri Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241001643449 Lactobacillus parakefiri Species 0.000 description 1
- 241000866650 Lactobacillus paraplantarum Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 230000036091 Metabolic activity Effects 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 206010034754 Petechiae Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 241000283011 Rangifer Species 0.000 description 1
- 206010037844 Rash Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 244000253911 Saccharomyces fragilis Species 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000009056 Telangiectasis Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 235000019961 diglycerides of fatty acid Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000000203 droplet dispensing Methods 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000003869 genetically modified organisms (GMOs) Nutrition 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 235000019960 monoglycerides of fatty acid Nutrition 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000000391 smoking Effects 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100001005 telangiectasia Toxicity 0.000 description 1
- 231100000730 tolerability Toxicity 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Abstract
The present invention is intended for the use of a probiotic composition comprising Bifidobacterium animalis subs. lactis (B. lactis), Bifidobacterium longum and Lactobacillus casei, particularly the strains B. lactis CECT 8145, B. longum CECT 7347 and/or L. casei CECT 9104, in the treatment and/or prévention of atopic dermatitis.
Description
USE OF PROBIQTICS IN THE TREATMENT AND/OR PREVENTION OF ATOPIC DERMATITIS
DESCRIPTION
The présent invention relates to a probiotic composition and the use of said composition for the treatment and/or prévention of atopie dermatitis. Therefore, the présent invention can be considered as encompassed within the field of medicine, particularly in the treatment of skin diseases.
STATE OF THE ART
Atopie dermatitis (AD) is a pruritic, inflammatory skin disease of chronic course, characterized by the development of lésions of eczema with a characteristic 15 pattern of distribution that affects patients with cutaneous hyperreactivity to various environmental factors that are harmless to nonatopic patients. Atopie patients often hâve personal or family history of asthma or allergie rhinitis or AD, and hâve elevated IgE sérum levels. Atopie dermatitis most often affects children, but can persist and / or onset may occur in adolescence or adulthood.
The prevalence of AD is between 4 and 20% of the population. There are great différences between rural or urban environments, the incidence being higher in the latter. The incidence of AD is probably increasing for the following reasons: Western lifestyle, increased maternai âge, pollution, maternai smoking and 25 reduced breastfeeding. Forty-five percent (45%) of children develop AD in the first six months of life and 85% in the first five years. When the disease starts in children under two years of âge, 20% hâve persistent symptoms at the âge of seven.
While atopie dermatitis is clinically manifest as eczema, both in its acute and chronic states, this disease présents great variability in: 1) the range of clinical manifestations; 2) the genetic basis of the same, and 3) the pathogenetic mechanisms underlying the clinical manifestations.
One of the most widespread hypothèses explaining the origin of atopie dermatitis spéculâtes that it is one of a number of manifestations, affecting the skin in this case, of a systemic process involving other organs and Systems of the human body, giving rise to a range of symptoms such as asthma, food allergy and allergie rhinitis, among others. In fact, a high percentage of patients with these diseases hâve elevated levels of IgE and eosinophils in peripheral blood although both the origin and clinical implications are unclear.
Regarding the pathophysiological mechanisms, the immune response is believed to play a major rôle in its origin. In fact, recent data implicate cutaneous dendritic cells (antigen-presenting cells) and the régulation of inflammatory-immune signais mediated by Th2 lymphocytes in the origin of the AD. The data indicate that the pathophysiological origin of AD can be found in these immunological mechanisms, involving both antigen-presenting cutaneous dendritic cells and immune régulation and inflammatory signais mediated by Th2 lymphocytes. What is not known at présent is the source of the stimulus triggering the immunological cascade that occurs in AD.
The disease has a wide range of clinical manifestations ranging from minor forms such as hand eczema to more serious forms such as érythrodermie rash. There are no spécifie changes of pathological or laboratory type, therefore AD diagnosis is clinical and the standard diagnosis follows the Hanifin-Rajka criteria (Hanifin JM, étal. Acta Derm Venereol 1980;92:44-7)
The clinical characteristics of AD are variable in relation to âge and are included in the diagnostic criteria; they include itching, eczema lésions and lésions from scratching.
Itching: one of the most important and consistent findings of atopy. Atopie pruritus is intense and usually causes outbreaks. Itching causes patients to injure themselves by scratching. While the cause of pruritus is not well understood, it appears to be due to the release of inflammatory mediators and cytokines.
Eczema: eczema lésions may be acute and chronic. Acute injuries are characterized by macules, papules and erythematous, vesicular, exudative and very pruritic plaques. Repeated scratching and abrasions resuit in chronic injuries, which are characterized by manifest skin thickening accompanied by lichénification and with apparent presence of dry fibrous papules.
Lichénification: characteristically lichenified skin lésions are observed, consisting of not well-defined plaques with skin thickening displaying marked skin folds and lines
Prurigo: small papules with a discreet bleb and marked galling that are the resuit of vigorous scratching.
Exfoliative dermatitis: cases of extensive atopy may clinically appear like generalized exfoliative dermatitis, included in the differential diagnosis of erythrodermas.
Besides establishing diagnosis, severity must be assessed or quantified. To this end, various methods and criteria hâve been developed to assess the severity and monitor response to treatment, in clinical trials and observational studies and even in clinical practice when the aim is to represent the patient's progress more accuracy than the description provided by the subjective perception of the patient, caregiver or doctor. In this respect, the most validated and used method is the so-called SCORAD index (Scoring Atopie Dermatitis) developed by the group European Task Force on Atopie Dermatitis in 1993 (European Task Force on Atopie Dermatitis. Severity scoring of atopie dermatitis: the SCORAD index.
Dermatology 1993; 186:23-31). It has proven to be the best method of assessing the severity of atopie dermatitis in comparative studies, and is also the most widely documented regarding validity, reproducibility, sensitivity and acceptability. The SCORAD is a scoring System that takes into account the extent and intensity of five types of basic AD lésions (erythema, edema/papule, oozing/crusting, excoriation and lichénification) and the symptoms ( itching and loss of sleep).
There is some discrepancy regarding SCORAD index values that define the different degrees of severity. Some Spanish groups consider mild, moderate or severe correspond to the SCORAD index scores <25, 25 to 40 or >40, respectively, while other authors, based on corrélations with laboratory tests, use the scores <20, 20 to 40 or >40, respectively to define mild, moderate and severe symptoms.
There is a consensus on the treatment of AD, aiming, in the first instance, to prevent itching and to eliminate the inflammatory lésion; and, secondly, to prevent relapses (Munoz F. 2002. JANO, 1432: 52-7; Boguniewitcz M, SchmidGrendelmeier P, and Leung DYM. 2006. J Allergy Clin Inmunol, 118: 40-3). To prevent itching and scratching, H1 antihistamines are prescribed, although effectiveness is not clearly demonstrated. The primary purpose of eczema treatment is to control the inflammatory lésion, which also helps control itching. Therefore topical corticosteroids of various strengths are used depending on the severity of the injury and the patient’s condition. Those with apparently better results are traditional H1 antihistamines that cause sédation (hydroxyzine, clemastine, dexchlorpheniramine) and new-generation H1 antihistamines (dexfenfluramine, loratadine, cetirizine, and dérivatives), which are less sédative but sometimes show results that do not differ with statistical significance from the placebo (Boguniewitcz M, et al 2006. Quoted ad supra).
Adverse effects of topical corticosteroids pose restrictions for use. Adverse reactions at the administration site are the most common. If applied periocularly, the following usually appear: skin atrophy, petechiae, atrophie striae, hypertrichosis, depigmentation, telangiectasia, folliculitis and glaucoma. Less frequently, more serious systemic adverse effects hâve also been described, such as the hypothalamic-pituitary adrenal-axis suppression, growth retardation or cushingoid.
Some patients’ lack of response to corticosteroids and their adverse effects hâve triggered the development of new drugs to treat inflammation. Among the best studied are topical calcineurin inhibitors (tacrolimus and pimecrolimus) Leung, DYM and Bleder, T. 2003, Lancet, 361: 151-60; Munoz, F. 2002, JANO, 1432: 52-7). However, there are still doubts about the safety of these drugs in longterm treatments. In fact, the prospectus of products containing tacrolimus or pimecrolimus for topical treatment of atopie dermatitis indicate they should only be used in children over two years of âge for whom the use of topical corticosteroids is not recommended or has previously failed.
The use of probiotics to treat AD has been studied in recent years in a limited number of pilot studies and results differ depending on the probiotic used and the âge of patients in the trial (Soo-Pk Kim, et al. 2014. Ann Allergy Asthma Immunol. 113: 217e226; Gerasimov, SV et al. 2010. Am J Clin Dermatol, 11:351 e361 ; Farid, R. et al. 2011. Iran J Pediatr. 21:225e230). The most recent studies, including a meta-analysis of previous publications, demonstrate the bénéficiai effect of probiotic use in certain circumstances related to âge, bacterial strain or combination of probiotics and dose used ((Farid, R. et al 2011 cited ad supra; Van del Aa LB, et al. 2010. Clin Exp Allergy. 40:795e804; Boyle, RJ et al. 2008. Cochrane Database Syst Rev, 4: CD006135: Lee, J. et al. 2008. J Allegy Clin Immunol. 121:116). The probiotics most studied terms of treating atopie dermatitis and preventing new outbreaks of the disease belong to the généra Bifidobacterium and Lactobacillus, as these seem to yield better results (Lee, J. et al. 2008. Quoted ad supra).
There is a well-known medical need to develop treatments of quality, that are safe and effective for the long-term treatment of AD, since atopie dermatitis affects an importance proportion of the population, with notable effects on their quality of life, which may be affected by medical complications, etc. Topical corticosteroids are considered to be a very effective treatment, but imply a high risk of adverse effects. The incorporation of new alternatives to topical corticosteroids (such as calcineurin inhibitors) responds to this need, although the risk of adverse effects with these new drugs has yet to be defined. Therefore, the prior art shows there is the need to develop new compositions that are useful in treating AD, which prove to be effective and lack the typical side effects ofthe drugs used to date.
DETAILED DESCRIPTION OF THE INVENTION
The authors of the présent invention hâve discovered that administering a probiotic composition that modifies the intestinal microbiota to an individual suffering from atopie dermatitis, together with the usual treatment, surprisingly allows remission and/or improvement of the évolution of outbreaks of atopie dermatitis in the individual. As shown in the examples accompanying the présent description, when the probiotic composition (comprising microorganisms of the généra Bifidobacterium and Lactobacillus) was administered together with the usual chronic treatment of patients with outbreaks of atopie dermatitis, an improvement in the SCORAD index of 82.36% was observed while the improvement in this index in the cases treated with the usual chronic treatment but without the probiotic composition was 28.4%, différences considered clinically and statistically significant. Moreover, the improvement produced by the probiotic composition occurred since the first month of intake, maintaining or increasing the différences in subséquent analysis for 2 and 3 months of treatment. Additionally, another advantage of treating AD with the probiotic composition of the invention is that corticosteroid use by patients in the group treated with said probiotic composition was lower than in the group receiving placebo.
In addition to this bénéficiai effect on disease progression in patients with an outbreak of atopis dermatitis, it was also observed that in the three months after discontinuation of treatment with the above-mentioned probiotic composition, individuals who had received treatment with said composition had fewer outbreaks and longer disease-free time-lapses than those patients who had not received treatment.
Thus the utility of the probiotic composition described herein for the treatment and/or prévention of atopie dermatitis is demonstrated.
The inventors hâve developed a number of inventive aspects that will be described in detail below.
Composition of the probiotic composition of the invention and its use in the treatment of atopie dermatitis (AD).
In one aspect, the présent invention relates to a probiotic composition that comprises microorganisms of Bifidobacterium animalis subs. lactis (hereinafter B. lactis), Bifidobacterium longum and Lactobacillus casei.
In the présent invention the term probiotic composition is that composition comprising at least one microorganism which, when ingested, interacts with the individual’s metabolism and produces a bénéficiai effect in the same. In the présent invention, the probiotic composition comprises the microorganisms B. lactis, B. longum and L. casei, hereinafter, probiotic composition of the invention.
B. lactis is a bacterium commonly used as a probiotic, found mostly in yogurt and other dairy products, including infant formula. The scientific classification of B. lactis is: Kingdom: Bacteria Division: Firmicutes Class: Actinobacteria, Order:
Bifidobacteria, Family: Bifidobacteriaceae, Genus: Bifidobacterium, Species:
Bifidobacterium animalis subsp. lactis.
L. casei is a bacterium commonly used as a probiotic, found mostly in yogurt and other dairy products, including infant formula. The scientific classification of L casei is: Kingdom: Bacteria Division: Firmicutes Class: Bacilli Order: Lactobacillales, Family: Lactobacillaceae, Genus: Lactobacillus, Species: Lactobacillus casei.
Moreover, B. longum is a Gram négative, catalase-negative bacterium, rounded in shape, located in the gastrointestinal tract, where it produces lactic acid. The scientific classification of B. longum is: Kingdom: Bacteria Division: Firmicutes Class: Actinobacteria, Order: Bifidobacteria, Family: Bifidobacteriaceae, Genus: Bifidobacterium, Species: Bifidobacterium longum.
In a particular embodiment, the probiotic composition ofthe invention comprises B. lactis CECT 8145 (and/or strains derived therefrom), B. longum CECT 7347 (and/or strains derived therefrom) and/or L. casei CECT 9104 (and/or strains derived therefrom).
B. lactis strain CECT 8145 was isolated from feces of a healthy breastfeeding child less than three (3) months old. This strain was deposited on 14 May 2012 under the Budapest Treaty in the Spanish Type Culture Collection as an International Depositary Authority (based in Building 3 CUE, Parc Cientîfic Universitat de Valencia, C/ Catedrâtico Agustin Escardino, 9, 46980 Paterna (Valencia) SPAIN). The deposit number assigned is CECT 8145.
L. casei strain CECT 9104 was isolated from feces of a healthy and breastfeeding child less than three (3) months old. This strain was deposited on 25 February 2016 under the Budapest Treaty in the Spanish Type Culture Collection as an International Depositary Authority (based in Building 3 CUE, Parc Cientîfic Universitat de Valencia, C/ Catedrâtico Agustin Escardino, 9,
46980 Paterna (Valencia) SPAIN). The deposit number assigned was CECT
9104.
B. longum strain CECT 7347 was isolated from feces of a healthy breastfeeding child less than three (3) months old and deposited on 20 December 2007 under the Budapest Treaty in the Spanish Type Culture Collection as the International Depository Authority (based in Building 3 CUE, Parc Cientific Universitat de Valencia, C/ Catedrâtico Agustin Escardino, 9, 46980 Paterna (Valencia) SPAIN). The deposit number assigned was CECT 7347.
The présent invention also contemplâtes those microorganisms or bacteria derived from the microorganisms B. lactis, B. longum and L. casei (or their corresponding strains B. lactis CECT 8145, L. casei CECT 9104 and B. longum CECT 7347) and that may be part of the probiotic composition of the invention as they retain the ability to reduce and/or improve the évolution of atopie dermatitis in individuals who suffer this pathology. Examples of strains or microorganisms derived from strains comprised within the probiotic composition of the invention may be mutants and genetically modified organisme which show variations in their genome compared to the genome of the strains of the invention, but which do not affect the ability of strains to reduce and/or improve the évolution of atopie dermatitis in the individual. Strains derived from B. lactis, B. longum and L. casei (or from strains of B. lactis CECT 8145, L. casei CECT 9104 and B. longum CECT 7347) can be naturally or intentionally produced by mutagenesis, as known in the art, such as for example, but not limited to, the growth of the parent strain in the presence of mutagenic agents or stressors or by genetic engineering directed to the modification, délétion and/or insertion of spécifie genes. Thus, as indicated above, the présent invention also contemplâtes genetically modified organisms derived from B. lactis, B. longum and L. casei (or from strains of B. lactis CECT 8145, L. casei CECT 9104 and B. longum CECT 7347), that retain the ability to reduce and/or improve the évolution of atopie dermatitis in an individual and, therefore, to be used in the treatment of atopie dermatitis. An example of a test to verify if an organism has the ability to reduce and/or improve the évolution of atopie dermatitis in an individual is described in the accompanying examples herein.
Furthermore, the présent invention, also contemplâtes cellular components, métabolites and molécules secreted by B. lactis, B. longum and L. casei or their corresponding strains B. lactis CECT 8145, L. casei CECT 9104 and/or B. longum CECT 7347 as well as compositions comprising said components, be they cells, métabolites or secreted molucules, and uses thereof for the treatment and/or prévention of atopie dermatitis. The cellular components of bacteria could include components of the cell wall (such as, but not limited to, peptidoglycan), nucleic acids, membrane components and other, such as proteins, lipids and carbohydrates and combinations thereof (such as lipoproteins, glycolipids or glycoproteins). Métabolites include any molécule produced or modified by the bacterium as a resuit of its metabolic activity during growth, its use in technological processes or during storage of the product (probiotic composition of the invention). Examples of these métabolites include, but are not limited to, organic and inorganic acids, proteins, peptides, amino acids, enzymes, lipids, carbohydrates, lipoproteins, glycolipids, glycoproteins, vitamins, salts, minerais and nucleic acids. Secreted molécules include any molécule secreted or released to the outside by the bacterium during growth, its use in technological processes (for example, food processing or drugs) or during storage of the product (the probiotic composition of the invention). Examples of these molécules include, but are not limited to, organic and inorganic acids, proteins, peptides, amino acids, enzymes, lipids, carbohydrates, lipoproteins, glycolipids, glycoproteins, vitamins, salts, minerais and nucleic acids.
As understood by experts in the art, the probiotic composition of the invention may be formulated for pharmaceutical administration, i.e., forming part of pharmaceutical products to be administered to the subject (for example orally, topically, etc.), and/or for food administration, i.e. forming part of the foods consumed in the subject’s diet. In the présent invention, said composition is for use to diminish, reduce, treat and/or prevent atopie dermatitis. Therefore, in a particular embodiment, the probiotic composition of the invention is a pharmaceutical composition and/or a nutritional composition.
The pharmaceutical composition is a set of components or compounds which is formed at least by microorganisms B. lactis, L. casei and B. longum, in particular by strains of B. lactis CECT 8145, and/or L. casei CECT 9104 and/or B. longum CECT 7347 (or strains derived therefrom) at any concentration and which additionally may comprise one or more components or compounds having any biological, pharmacological and/or veterinary activity which, upon administration to a subject, may further increase, enhance and/or promote the activity of the strains included in the probiotic composition of the invention. As understood by one skilled in the art, the additional components or compounds must be compatible with the strains of the probiotic composition of the invention. In the context of the présent invention, the term pharmaceutical composition also encompasses veterinary compositions.
Examples of useful components or compounds used in the treatment of atopie dermatitis which can be part of the pharmaceutical composition include, but are not limited to, traditional H1 antihistamines (e.g. hydroxyzine, clemastine and dexchlorpheniramine), recently developed H1 antihistamines (e.g. dexfenfluramine, loratadine, cetirizine, and dérivatives) and calcineurin inhibitors (e.g. tacrolimus and pimecrolimus).
In a particular embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and/or excipient.
The term excipient refers to a substance that helps the absorption of any components or compounds of the probiotic composition of the invention, namely, of strains of the invention, or stabilizes the components or compounds and/or assists the préparation of the pharmaceutical composition in the sense of giving it consistency or flavors to make it more pleasant. Thus, the excipients may hâve the function, by way of example but not limited thereto, of binding the components (for example, starches, sugars or cellulose), sweetening, coloring, protecting the active ingrédient (for example, to insulate it from air and/or moisture), filling a pill, capsule or any other présentation or a disintegrating function to facilitate dissolution of the components, without excluding other excipients not listed in this paragraph. Therefore, the term excipient is defined as a material, included in the galenic forms, which is added to the active ingrédients or their associations to enable their préparation and stability, modify their organoleptic properties and/or détermine the physico-chemical properties of the pharmaceutical composition and its bioavailability. The pharmaceutically acceptable excipient must allow the activity of components or compounds of the pharmaceutical composition, that is, must be compatible with the strains of the invention.
The galenic form or pharmaceutic form is the configuration to which the active ingrédients and excipients are adapted to provide a pharmaceutical composition or a drug. It is defined by the combination of the form in which the pharmaceutical composition is presented by the manufacturer and the form in which it is administered.
The vehicle or carrier is preferably an inert substance. Carrier functions are to facilitate the incorporation of other components or compounds, allow better dosage and/or administration and/or give consistency and form to the pharmaceutical composition. Therefore, the carrier is a substance used in the drug to dilute any of the components or compounds of the pharmaceutical composition of the présent invention to a given volume or weight; or that even without diluting these components or compounds, it is able to allow better dosage and administration and/or give consistency and form to the drug. When the présentation is liquid, the pharmaceutically acceptable carrier is the diluent. The carrier can be natural or unnatural. Examples of pharmaceutically acceptable carriers include, without being limited thereto, water, sait solutions, alcohol, vegetable oils, polyethylene glycols, gélatine, lactose, starch, amylose, magnésium stéarate, talc, surfactants, silicic acid, viscous paraffin, perfume oil, monoglycerides and diglycerides of fatty acids, fatty acid esters petroetrals, hydroxymethylcellulose, polyvinylpyrrolidone and the like.
Furthermore, the excipient and the carrier must be pharmacologically acceptable, i.e., the excipient and the carrier are permitted and evaluated so as not to cause damage to the subject to whom it is administered. Additionally, the carrier and / or vehicle can be natural, i.e., naturally occurring, or unnatural, that is, they may or may not occur or in nature but, if they are in nature, are not naturally found in combination with the strains of the invention.
In each case the présentation of the pharmaceutical composition will be adapted to the type of administration used. Thus, the composition may be presented in the form of solutions or any other form of clinically permissible administration and in a therapeutically effective amount. The pharmaceutical composition can be formulated into solid, semisolid or liquid préparations, such as tablets, capsules, powders, granules, solutions, suppositories, gels or microspheres. In a particular embodiment, the pharmaceutical composition is formulated for administration in liquid form or in solid form.
In another particular embodiment, the solid formulation is selected from the group consisting of tablets, lozenges, sweets, chewable tablets, chewing gums, capsules, sachets, powders, granules, coated particles or coated tablets, tablet, pills, troches, gastro-résistant tablets and capsules and dispersible strips and/or films.
In another particular embodiment, the liquid formulation is selected from the group consisting of oral solutions, suspensions, émulsions and syrups.
Likewise, various Systems are known that can be used for sustained-release administration of the probiotic composition of the invention, including, for example, the encapsulation in liposomes, microbubbles, microparticles or microcapsules and the like, of the same. The suitable sustained-release forms as well as materials and methods for their préparation are well known in the state of the art. Thus, the orally administrable form of the probiotic composition of the invention is in a sustained-release form further comprising at least one coating or matrix. The sustained release coating or matrix includes, without limitation to, natural semisynthetic or synthetic polymers, water-insoluble or modified, waxes, fats, fatty alcohols, fatty acids, natural, semisynthetic or synthetic plasticizers or a combination of two or more of ail the abovementioned. Enteric coatings can be applied using conventional processes known to those skilled in the art.
In addition to what has been described above, the présent invention also encompasses the possibility that the probiotic composition of the invention may be administered to a subject together with other components or compounds, although these are not part of the probiotic composition. Examples of such components or compounds hâve been mentioned in preceding paragraphs.
In the event that the probiotic composition of the invention is formulated as a nutritional composition, said nutritional composition may be a food or be incorporated into a food or food product intended for both human and animal consumption. Thus, in a particular embodiment, the nutritional composition is selected from between a food (which may be a food for spécifie nutritional purposes or médicinal food) and a nutritional supplément.
In the présent invention, the term nutritional composition refers to that food, which regardless of providing nutrients to the subject who consumes it, beneficially affects one or more bodily functions, so as to bestow upon said subject better health and wellness. In the présent invention, said nutritional composition is intended to ease, reduce, treat and/or prevent atopie dermatitis.
The term supplément, synonymous with any of the terms dietary supplément, nutritional supplément, food supplément, or alimentary supplément or “alimentary complément” refers to products or préparations whose purpose is to supplément the normal diet consisting of sources of concentrated nutrients or other substances with a nutritional or physiological effect on the subject. In the présent invention, the substance which has a nutritional or physiological effect on the individual when the food complément is ingested are the microorganisms B. lactis, L. casei and B. longum, in particular the strains B. lactis CECT 8145, and/or L. casei CECT 9104 and/or B. longum CECT 7347, which are part of the probiotic composition of the invention. The food supplément may be in single or combined form, and may be marketed in dosage form, i.e. in capsules, pills, tablets and other similar forms, sachets of powder, ampoules of liquids and drop dispensing bottles and other similar forms such as liquids and powders designed to be taken in a single dose.
There is a wide range of nutrients and other éléments that may be présent in dietary compléments including, but not limited to, vitamins, minerais, amino acids, essential fatty acids, fiber, enzymes, plants and plant extracts. Since their rôle is to complément the supply of nutrients in a diet, they should not be used as a substitute for a balanced diet and intake should not exceed the daily dose expressly recommended by the doctor or nutritionist. The probiotic composition can also be part of the so-called food for spécial groups, i.e. foods that meet spécifie nutritional needs.
Examples of foods that may comprise the probiotic composition of the invention (microorganisms B. lactis, L. casei and B. longum, in particular strains B. lactis CECT 8145, and/or L. casei CECT 9104 and/or B. longum CECT 7347 (or strains derived therefrom)) include, but are not limited to, feed, dairy products, vegetable products, méat products, snacks, chocolatés, drinks, baby food, cereals, fried foods, industrial bakery products and biscuits. Examples of milk products include, but are not limited to, products derived from fermented milk (for example, but not limited to, yogurt or cheese) or non-fermented milk (for example, but not limited to, ice cream, butter, margarine or whey). The vegetable product is, for example, but not limited to, a cereal in any form of présentation, fermented (for example, but not limited to, soy yogurt or oat yogurt) or unfermented, and a snack. The beverage may be, but is not limited to, non-fermented milk. In a particular embodiment, the food product or food is selected from the group consisting of fruit or vegetable juices, ice cream, infant formula, milk, yogurt, cheese, fermented milk, powdered milk, cereals, baked goods, milk-based products, méat products and beverages.
Additionally, the probiotic composition of the invention may comprise other microorganisms in addition to B. lactis, L. casei and B. longum, in particular strains B. lactis CECT 8145, and/or L. casei CECT 9104 and/or B. longum CECT 7347. Thus, in a particular embodiment, the probiotic composition of the invention further comprises a microorganism selected from the group consisting of Lactobacillus sp., Streptococcus sp., Bifidobacterium sp., Saccharomyces sp., Kluyveromyces sp. and combinations thereof.
In another even more particular embodiment, the Lactobacillus sp. is L. rhamnosus, L. delbrueckii subsp. bulgaricus, L. kefir, L. parakefir, L. brevis, L. casei, L. plantarum, L. fermentum, L. paracasei, L. acidophilus, L. paraplantarum or L. reuterr, Streptococcus sp. is Si. thermophilus', Bifidobacterium sp. is B. longum, B. breve, B. bifidum, B. catenulatum, B. adolescentis or B. pseudocatenulatum; Saccharomyces is S. cerevisiae or S. boulardii; or Kluyveromyces sp. is K. lactis or K. marxianus.
In another particular embodiment, the probiotic composition of the invention is administered to a subject through the diet.
As understood by one skilled in the art, the microorganisms B. lactis, L. casei and B. longum, in particular the strains B. lactis CECT 8145, L. casei CECT 9104 and/or B. longum CECT 7347, hâve to be présent in the probiotic composition of the invention in a therapeutically effective amount so that they can exert their effect of easing, reducing, treating and/or preventing atopie dermatitis.
In the présent invention therapeutically effective amount is that amount of the component or compound of the pharmaceutical composition, which when administered to a subject, is sufficient to produce the desired effect. Said component or compound of the pharmaceutical composition refers to the microorganisms B. lactis, L. casei and B. longum, in particular the strains B. lactis CECT 8145, L. casei CECT 9104 and/or B. longum CECT 7347. As known by experts in the matter, the therapeutically effective amount may vary depending on, for example, âge, body weight, general health, sex and diet of the subject, as well as according to the mode and time of administration, excrétion rate ordrug combination, among other factors.
Thus, in a particular embodiment, the total concentration of microorganisms of B. lactis, L. casei and B. longum, in particular the strains B. lactis CECT 8145, and/or L. casei CECT 9104 and/or B. longum CECT 7347 in the composition is between 103 and 1012 cfu, preferably 109cfu. In another particular embodiment, the dose of administration of microorganisms B. lactis, L. casei and B. longum, in particular B. lactis CECT 8145, L. casei CECT 9104 and/or B. longum CECT 7347, in the composition is between 106 and 1012 cfu / day, preferably 109 cfu / day, and in another even more particular embodiment, the administration régime is at least once daily, in particular twice daily, and more in particular, three times a day, one with each food intake (breakfast, lunch and dinner).
In another particular embodiment, the concentration of B. longum, particularly B. longum strain CECT 7347, with respect to the total concentration of microorganisms présent in the composition is selected from any of the following values: 10%, 15 %, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or 80%. In another particular embodiment, the concentration of B. lactis, particularly B. lactis strain CECT 8145, with respect to the total concentration of microorganisms présent in the composition is selected from any of the following values: 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or 80%. In another particular embodiment, the concentration L. casei in particular L. casei strain CECT 9104, with respect to the total concentration of microorganisms présent in the composition is selected from any of the following values: 10%, 15 %, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or 80%. As understood the by the expert, the composition of the invention comprises any combination of the concentrations for each ofthe microorganisms described above.
In another particular embodiment, the concentration of B. longum with respect to the total concentration of microorganisms présent in the composition is at least between 25% and 45%, preferably at least 35%; B. lactis concentration with respect to the total concentration of microorganisms is at least between 25% and 45%, preferably at least 35%; and/or L. casei concentration with respect to the total concentration of microorganisms is between 20% and 40%, preferably 30%.
The probiotic composition of the invention is useful in the treatment and/or prévention of atopie dermatitis in an individual, as well as improving the évolution of atopie dermatitis once intake of the probiotic composition described herein is suspended.
Thus, another object described herein relates to the probiotic composition described herein for use as a drug.
The term drug, as used herein, refers to any substance used for prévention, diagnosis, alleviation, treatment or cure of diseases in humans and animais. In the context of the présent invention the disease is AD.
Another object herein described relates to probiotic composition such as described above, in the treatment and/or prévention of AD in an individual suffering from this disease.
In the présent invention the term subject is équivalent to the term individual; so both terms can be used interchangeably herein. Subject means, in addition to any individual, any animal belonging to any species. Examples of subjects include, but are not limited to, animais of commercial interest such as birds 5 (hens, ostriches, chicks, geese, partridges, etc.); rabbits, hares, pets (dogs, cats, etc.); sheep, goat cattle (goats, etc.); swine (boars, pigs, etc.); equine livestock (horses, ponies, etc.); cattle (bulls, cows, oxen, etc.); animais of hunting interest, such as stags, deer, reindeer, etc.; and humans. However, in a particular embodiment, the subject is a mammal, preferably the mammal is a 10 human being of any race, sex or âge.
In the présent invention the term prévention means to avoid occurrence of the disease or pathological condition in an individual, particularly when the individual has prédisposition for the pathological condition, but has not yet been 15 diagnosed. In the présent invention, the disease or pathological condition is an outbreak of atopie dermatitis.
In the présent invention, the term treat or treatment comprises inhibiting the disease or pathological condition, i.e., stopping its development; relieving the disease or pathological condition, i.e., causing régression of the disease or 20 pathological condition; and/or stabilizing the disease or pathological condition in an individual. In the présent invention, the disease or pathological condition is atopie dermatitis.
In the présent invention the term atopie dermatitis (AD) is understood as 25 inflammatory dermatoses, pruritic, chronic course, characterized by the development of lésions of eczema with a characteristic pattern of distribution that affects individuals with cutaneous hyper-reactivity to various environmental -s. factors that are harmless for non-atopic individuals. Being a chronic inflammatory process there are outbreaks of inflammatory nature due to for this 30 great skin hyperactivity causing lésions both in skinfold areas and in areas of extension, following a pattern of acute or subacute eczema. Atopie dermatosis may manifest in many forms and places other than the skin. 19179
Method of treatment and/or prévention of inflammatory skin diseases
Another aspect, the invention relates to a method for the treatment of atopie dermatitis in a subject, hereinafter, method of treatment of the invention, comprising the administration of the probiotic composition described in the présent invention to an individual who présents atopie dermatitis.
Ail particular terms, définitions and embodiments of previous inventive aspects are applicable to the treatment method of the invention.
Throughout the description and claims the word comprise and its variants are not intended to exclude other technical characteristics, additives, components or steps. For those skilled in the art, other objects, advantages and characteristics of the invention will become apparent, in part, from the description and, partly, from putting into practice the invention. The following examples and figures are provided by way of illustration and are not intended to limit the scope of the présent invention.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is a diagram showing the analysis of the main components of the microbiological profiles of stool samples taken from patients with atopie dermatitis (square symbol and black) compared to healthy individuals belonging to enterotype 1 (circular symbol and dark gray), to enterotype 2 (triangular symbol and gray) and to enterotipo3 (rhombic symbol and light gray).
Figure 2 is a diagram showing the variability analysis of stool samples of patients with dermatitis compared with the healthy population in each of the enterotypes. The figure shows statistical significances after applying a Wilcoxon test.
Figure 3 is a diagram showing the principal components analysis of patients with dermatitis or classified as belonging enterotype 1 (square symbol and black) compared to samples from healthy population of enterotype 1 (circular symbol and gray). The genres most represented in the samples located in the upper right part of the figure shown in black and those who are underrepresented in this situation are shown in gray. With respect to the samples located in the lower left corner, the trend is the opposite: the less abundant are marked in black while the abundant are marked in gray.
Figure 4 is a diagram showing the principal components analysis of patients with dermatitis or classified as belonging enterotype 2 (square symbol and black) compared to samples from the healthy population of enterotype 2 (circular symbol and gray). The genres most represented in the samples located in the upper right-hand part of the figure are shown in black while those underrepresented in this situation are shown in gray. With respect to the samples located in the lower left-hand corner, the trend is the opposite: the less abundant are marked in black and the abundant are those marked in gray.
Figure 5 is a diagram showing the principal components analysis of patients with dermatitis or classified as belonging enterotype 3 (square symbol and black) compared to samples from the healthy population of enterotype 3 (circular symbol and gray). The genres most represented in the samples located in the upper right-hand part of the figure are shown in black and those underrepresented in this situation are shown in gray. With respect to the samples located in the lower left-hand corner, the trend is the opposite: the less abundant are marked in black and the abundant are marked in gray.
Figure 6 shows the results of SCORAD index a month after starting treatment with the probiotic composition of the invention or placebo. The results show the absolute value of SCORAD for each treatment group (Figure 6A) and the % réduction in the SCORAD index during the course of treatment in both groups (Figure 6B). V3, check-up at 1 month. Group A, group consuming the placebo;
Group B, group consuming the probiotic composition.
Figure 7 shows the SCORAD index results within two months of starting treatment with the probiotic composition ofthe invention or placebo. The results show the absolute value of SCORAD for each treatment group (Figure 7A) and SCORAD % réduction during the course of treatment in both groups (Figure 7B). V5, check-up month 2. Group A, group consuming the placebo; Group B, group consuming the probiotic composition.
Figure 8 shows the results of SCORAD index three months (end of trial) after starting treatment with the probiotic composition of the invention or placebo. The results show the absolute value of SCORAD in each treatment group (Figure 8A) and SCORAD % réduction in both groups during the treatment time (Figure 8B). V7, check-up at 3 months. Group A, group consuming placebo; Group B, group consuming the probiotic composition.
Figure 9 shows the % of improvement in the SCORAD index during the trial period measured at one month, two months and three months (end of trial) as of baseline. The différences between the two treatment groups were statistically significant as of the first month and these différences increased at months two and three of the trial. The dashed line shows the group consuming the probiotic composition; continuous line, group consuming the placebo.
Figure 10 shows the trends in the SCORAD index over time, measured at one month, two months and three months (end of trial) after baseline. The différences between the two treatment groups are statistically significant. The dashed line represents the group consuming the probiotic composition; the continuous line shows the placebo group.
Figure 11 shows the trend in the number of patients suffering from a new outbreak of atopie dermatitis (Figure 11 A), the total number of patients with new outbreaks of atopie dermatitis (Figure 11 B), and the percentage of patients free from new outbreaks (Figure 11C); during the three months follow-up after stopping treatment intervention with placebo or probiotic composition of the invention. The différences between the two intervention groups are statistically significant in the three-month évaluation after the start of monitoring for the three variables analyzed. Black line: patients who received placebo; gray line, patients who received the probiotic composition.
EXAMPLES
The invention will be illustrated by tests performed by the inventors, which show the properties of the probiotic composition of the invention.
EXAMPLE 1: Détermination of bacterial microbiota in patients with AD
1.1 MATERIAL AND METHODS
Based on the stool samples of 49 patients with dermatitis, extraction of genetic material (DNA) was performed using a combination of mechanical and enzymatic disruption of cell walls and membranes in order to increase the yield of extraction and not bias the presence of bacteria with cell wall (Gram +). The genetic material obtained by extraction was measured to assess quality and quantity using a Nanodrop 2000 ThermoScientific to inspect ratios 260/280 and 260/230 indicating the extraction quality (presence of PCR inhibitors, pigment, etc.). Later, after verifying the quality of the same, massive sequencing libraries were conducted, capturing the hypervariable région V3-V4 of the bacterial 16s rRNA gene (based on Klindworth A, et al. (2013) Nucleic Acids Res 41: e1) according to the protocol described by Illumina for analysis of the microbial composition based on the capture of 16s rRNA. Each library was quantified with Quant-iT PicoGreen by Invitrogen and mixed equimolarly for subséquent sequencing.
Samples were sequenced in MiSeq platform in a combination of 300 PairedEnd cycles. The resulting FASTQ files were treated to ensure high quality sequence analysis. For this purpose, a quality control was conducted consisting of:
1. Joining the ends to reconstruct unique sequences using the program 'pear' vO.9.6. (Zhang J, et al (2014) Bioinformatics 30 (5):614-20).
2. Elimination of sequencing adapters and capture primers from the hypervariable régions V3 and V4 with the program cutadapt version 1.9.1. (Martin M (2010) EMBnet.journal [S.L.], 17 (1): 10-12. ISSN 22266089.).
3. Elimination of low quality sequences using FASTX-ToolKit version 0.91.
4. Elimination of chimeras produced by PCR using the UCHIME program (Dec 2015) (Edgar RC, et al (2011) Aug 15; 27 (16): 2194-200) and the last database of chimeras.
The resulting samples were compared against a sequence database of 16S rRNA (NCBI) using a BLAST type local alignment (Altschul SF, et al (1990) J. Mol Biol. 215: 403-410).
Each of the sequences for which a score was obtained of ninety-five percent (95%) identity was inspected at different taxonomie of levels: Phylum, Family, Genus and Species.
The R statistical package was used for statistics, to construct graphs for principal component analysis (PCA).
It is interesting to note that there is great variation in microbial populations of the digestive tract of each individual, epidemiological studies suggest that the microbiota of almost ail of them can be classified as belonging to three distinct categories known as enterotypes (Arumugam et al., (2011 ) Nature 473:174180). This classification is based on the prédominance in each of these three enterotypes of members of the généra Bacteroides, Prevotella or Ruminococcus. Enterotype 1 (ent1 ) is referred to when the Bacteroides genus is prédominant, enterotype 2 (ent2) if the Prevotella genus is prédominant and enterotype 3 (ent3) when the Ruminococcus genus is prédominant (Dave et al., (2012). Trans. Res. 160, 246-257).
II. RESULTS
As mentioned above, the microbial composition was analyzed in stool samples from individuals suffering from atopie dermatitis as compared to stool samples from healthy individuals.
The results show that, as can be seen in Figure 1, microbiological profiles of samples from patients with AD are doser to healthy individuals with enterotype 3 than to the other healthy individuals. As shown top left of the abovementioned Figure 1, the patients with AD (quadricular and black symbol) cluster together with healthy individuals with enterotype 3 (rhombic and light gray symbol), but with greater dispersion in the case of AD patients than in healthy individuals with enterotype 3. By contrast, individuals in the healthy population with enterotype 1 (circular and dark gray symbol) or enterotype 2 (triangular and gray symbol) cluster in the part top, from left to right, and on the left side, top down, respectively. It is also noticeable that samples clustering on the righthand side of the graph hâve a greater abundance of the Bacteroides genus and fewer Prevotella and Faecalibacterium, while samples clustering at the top of the graph in Figure 1 présent a clear absence of Prevotella; hence samples from healthy patients with enterotype 2 (greater abundance of species of the Prevotella genus) are located in the lower left-hand corner and show an increase in Faecalibacterium and Ruminococcus. These data enable us to state that the microbiome of patients with AD is doser to that of healthy individuals with enterotype 3, but with a different composition and microbial variability.
This different variability and microbial composition among healthy individuals with enterotype 3 and AD patients is noticeable in greater detail when the variability of bacterial populations is analyzed in samples of the healthy population (with each of the three separate enterotypes) for samples of patients with AD by Shannon index (Figure 2). As shown in Figure 2, in general, patients with AD hâve greater variability compared to healthy individuals, having a médian and interquartile range of 2.97 (2.84 to 3.06) for patients with atopie dermatitis and 1.99 (1.37 to 2.52); 2.14 (1.50 to 2.62) and 2.23 (1.91 to 2.57) for healthy individuals with enterotypes 1, 2 and 3, respectively. Specifically, AD patients hâve a significantly higher bacterial variability than that présent in any of the enterotypes of healthy individuals, because in ail cases p <0.0001 on comparing the microbial variability of AD patients with that of the healthy population with different enterotypes.
In order to détermine the bacteria that differentiate the healthy population from the population with atopie dermatitis, we proceeded to classify patients with atopie dermatitis based on the prédominance of Bacteroides (ent1 ), Prevotella (ent2) or Ruminococcus (ent3). Subsequently, we examined whether there were différences between each of the different enterotypes of the healthy population regarding the different enterotypes in people with AD. Firstly, from the total of 49 patients with AD, 25 were classified as ent1 ; two as ent2; and 22 as ent3. Similarly, of the 324 healthy subjects, 298 were classified as ent1 ; 21 as ent2; and five as ent3. Then bacterial variability was analyzed within each enterotype, 1,2 or 3 among AD patients as compared to healthy subjects.
Figure 3 shows the bacterial variability among healthy subjects versus patients with AD, ail with enterotype 1. As shown in Figure 3, healthy individuals hâve greater abundance of Bacteroides than AD patients, while patients with AD display greater abundance of the généra Faecalibacterium, Bifidobacterium and, especially, low abundance of species of the genus Alistipes.
Figure 4 shows the bacterial variability among healthy subjects versus patients with AD, ail with enterotype 2. In this case, it is not possible to differentiate, in terms of bacterial généra, among AD patients with enterotype 2 from healthy individuals with the same enterotype. On the other hand, this figure shows the low level of AD patients who are classified as enterotype 2.
As is the case for healthy individuals and AD patients with enterotype 1, in AD patients classified as enterotype 3 (Figure 5) there are appréciable différences between patients with AD compared to healthy individuals. As shown in Figure 5, AD patients hâve fewer species belonging to the Ruminococcus genus than healthy patients, as well as less abundance of species belonging to the genus Faecalibacterium.
Given ail the results shown above, it is clear that the microbiota of patients with AD is different in composition and variability compared to the microbiota of the healthy population. It has also been shown that there are fewer patients with AD belonging to enterotype 2, and furthermore that patients with AD also display increased microbial variability, but with fewer bacteria belonging to species of the important généra in each enterotype, specifically the généra Bacteroides and Ruminococcus for enterotypes 1 and 3, respectively.
EXAMPLE 2: Analysis of the efficacy of the probiotic composition of the invention in the prévention and I or treatment of atopie dermatitis (AD).
I. MATERIALS AND METHODS
In order to evaluate the efficacy of the probiotic composition of the présent invention in reducing symptoms, together with the use of topical corticosteroids in the treatment of atopie dermatitis, a randomized pilot clinical, double-blind, placebo-controlled trial was conducted in a group 20 patients suffering atopie dermatitis aged between 4-17 years.
To do so, patients enrolled in the trial were diagnosed with atopie dermatitis according to the criteria of Hanifin and Rajka (Hanifin JM, et al Acta Derm Venereol 1980; 92:. 44-7), fulfilling ail the inclusion criteria and none of exclusion criteria established in the trial. Trial subjects also used, or might use, topical corticosteroids to treat outbreaks of atopie dermatitis, along with other active ingrédients used as normal treatment, such as émollients, systemic corticosteroids, antihistamines, etc.
Each patient was assigned to either the treatment or placebo group using stratified 1:1 randomization by blocks taking into account the variables: sex, âge, family history of first degree of consanguinity of atopy or atopie dermatitis and onset of atopie dermatitis before four years of âge.
The probiotic composition of the invention comprises Bifidobacterium lactis CECT 8145, Bifidobacterium longum CECT 7347 and Lactobacillus casei CECT 9104, formulated in a sugar and maltrotexina tapioca base, containing 5x1010 cfu / gram.
The form and appearance of the placebo administered was the same as that of the composition of the invention, but contained only tapioca maltodextrin and sugar.
The dosage regimen of the probiotic composition of the invention or placebo was one capsule per day.
For the treatment of outbreaks of atopie dermatitis that might be experienced by patients enrolled in the trial, méthylprednisolone aceponate was used as a topical corticosteroid, and duration of such treatment did not exceed two weeks. Deflazacort was prescribed if treatment with systemic corticosteroids was required. Desloratadine was used to treat itching, and a commonly used antibiotic such as fusidic acid was used for cases of infected atopie dermatitis.
The treatment period lasted twelve weeks from the recruitment of patients up until the last check-up. After the trial inclusion check-up (baseline) and assignment of treatment (treatment group or placebo), seven check-ups were programed, taking place at weeks 4, 8 and 12 from beginning treatment with the composition of the invention or with the placebo. During these check-ups the SCORAD index was evaluated; and at weeks 2, 6 and 10 each patients Data Collection Logbook (DCL) was updated.
Ail médications taken by the patient during the trial were recorded in the patients medical records and in the DCL, specifying the doses, route of administration and duration of treatment (start and end dates), and including médication. Additionally, each check-up was recorded in the DCL as well as the tally of retumed capsules. Table 1 shows the démographie and clinical characteristics of patients at baseline in each treatment group. Table 2 shows the timeline ofthe trial.
Table 1. Baseline démographie and clinical characteristics of the patients in each treatment group.
| Treatment | Average | SD | SEM | |
| Age | Placebo | 8.96 | 3.940 | 0.804 |
| Composition | 9.35 | 3.577 | 0.702 | |
| Scorad | Placebo | 31.6417 | 5.05129 | 1.03109 |
| Composition | 33.3077 | 3.51351 | .68906 | |
| lgE_Baseline | Placebo | 292.08 | 636.537 | 129.933 |
| Composition | 428.44 | 723.861 | 144.772 | |
| Eosin_Baseline | Placebo | 4.73 | 4.274 | 0.872 |
| Composition | 4.96 | 5.799 | 1.160 | |
| V2 Total Corticoïdes* | Placebo | 3.68 | 4.224 | 0.901 |
| Composition | 3.00 | 3.240 | 0.648 | |
| V2 Total Antihistamines* | Placebo | 0.32 | 0.780 | 0.166 |
| Composition | 1.28 | 2.072 | 0.414 |
*: Days of treatment in 2 weeks; SD: standard déviation; SEM: standard error of mean.
Table 2. Clinical Trial Protocol.
| Check-ups | 0/1 | 2 | 3 | 4 | 5 | 6 | 7 |
| Weeks | 0 | 2 | 4 | 6 | 8 | 10 | 12 |
| Inclusion/exclusion criteria | X | ||||||
| Signed informed consent | X | ||||||
| Medical record | X | ||||||
| Physical examination | X | X | X | X | |||
| Pregnancy test | X | X | |||||
| Complementary examinations | X | X | |||||
| SCORAD | X | X | X | X | |||
| Treatment (probiotic composition or placebo) | X | X | X | ||||
| Data collection logbook | X | X | X | X | |||
| Delivery of treatment | X | X | X | ||||
| Return and tally of unconsumed treatment | X | X | X | ||||
| Assessment of adverse events | X | X | X | X | X | X |
Ail statistical analyzes performed to obtain the final results shown below were carried out using SPSS 20.0 software.
Additionally the trial was undertaken in accordance with the Déclaration of Helsinki, as amended in successive world assemblies. The medical record and informed consent letter was obtained for ail participants (signed by the patient 10 or his/her guardian or legal représentative) in accordance with the Déclaration of Helsinki and approved by an ethics and institutional research committee.
II. RESULTS
First we analyzed whether the samples included in each study group were homogeneous, i.e., placebo group and the group receiving the probiotic composition of the invention. Table 3 demonstrates that this requirement was met as no différences were found between any of the variables analyzed for each study group.
Table 3. Homogeneity ofthe two samples. Trial statisticsa
| Age | SCORAD | V2 Total Corticosteroids* | V2 Total Antihistamines* | |
| Mann-Whitney U test | 286.500 | 260.500 | 271.000 | 223.500 |
| Wilcoxon W | 586.500 | 560.500 | 596.000 | 476.500 |
| Z | -0.497 | -1.000 | -0.088 | -1.435 |
| Asymptotic Sig. (bilateral) | 0.619 | 0.317 | 0.930 | 0.151 |
a Variable grouping: no différences occur in main variab es at baseline; *: Days of treatment in 2 weeks.
As mentioned above mean values (mean and médian) and ± standard déviation (SD) were calculated for global data at baseline, at one month and at two and three months of treatment. The values presented by the patient at each of these time points were compared with those taken at the beginning of the trial using the Wilcoxon test.
Effectiveness of the composition of the invention a month after starting treatment
After one month of treatment the SCORAD index was analyzed, comparing values between groups as well as baseline values. Table 4 shows the changes in value of absolute numbers and as a percentage.
Table 4. SCORAD index one month after starting treatment with the probiotic composition of the invention or placebo.
| Treatment | SCORAD 1 month | % change SCORAD 1 month | |
| Placebo | Mean | 25.8500 | 16.0015 |
| SD | 8.02355 | 23.17611 | |
| Médian | 24.8500 | 18.0150 | |
| Composition | Mean | 19.6182 | 41.7586 |
| SD | 7.33580 | 19.27088 | |
| Médian | 19.5000 | 40.8150 | |
| Mann-Whitney U test | 124.500 | 79.000 | |
| Wilcoxon W | 377.500 | 289.000 | |
| Z | -2.406 | -3.551 | |
| Asymptotic Sig. (bilateral) | 0.016 | 0.000 |
As shown by the results in Table 4 and Figure 6, after a month of treatment there were significant différences in the SCORAD index for the placebo group compared to the group treated with the probiotic composition of the invention. Figures 7 and 8 show changes in the SCORAD index at check-ups corresponding to two months (Figure 7) and three months (Figure 8) for 10 treatment compared to baseline between the group treated with the probiotic composition ofthe invention and the placebo group.
Figure 9 shows that the group treated with the composition of the invention has a lower SCORAD index measured at one month, two months and three months 15 from baseline as compared to the placebo group. As seen in Figure 9, the différences between the two treatment groups are statistically significant already as of the first month of treatment, with these différences increasing at 2 (v5) and 3 (V7) months from baseline.
Figure 10 shows the trends in the SCORAD index measured at one (V3), two (V5) and three (V7) months after the start of the trial. The différences between the group treated with the composition of the invention and the placebo group were statistically significant, demonstrating the advantages of using the composition in the treatment in patients with AD.
Regarding the use of topical corticosteroids in each study group, at one month of treatment, no statistically significant différences were observed between the two treatment groups for the variable days of use of topical corticosteroids (Table 5) on comparing both treatment groups by the Wilcoxon test with a statistical significance level of five percent (5%). By contrast, a trend was observed when topical corticosteroids were not used, which was greater in the group treated with the probiotic composition of the invention compared to the placebo group, specifically at months 2 and 3 of the trial. Notably, it did not reach statistical significance mainly due to the trial sample size.
Table 5. Analysis of topical corticosteroids used in each treatment group one month after the start of the trial. The grouping variable used to obtain the data shown is the kind of treatment, i.e., probiotic composition of the invention or placebo.
| Statistical analysis | V3 Total days of corticoid treatment |
| Mann-Whitney U test | 210.500 |
| Wilcoxon W | 441.500 |
| Z | -0.512 |
| Asymptotic Sig. (bilateral) | 0.108 |
No statistically significant différences between the two treatment groups, i.e., probiotic composition of the invention versus placebo, were observed on analyzing the variable for days of antihistamine use in the first month of treatment (Table 6). This variable was analyzed using the Wilcoxon test with a five percent (5%) level of statistical significance for each treatment group.
Table 6. Analysis of antihistamines used in each treatment group one month after baseline. The grouping variable used to obtain the data shown is the type of treatment: probiotic composition ofthe invention versus placebo.
| Statistical analysis | V3 Total days of antihistamine treatment |
| Mann-Whitney U test | 220.500 |
| Wilcoxon W | 473.500 |
| Z | -0.578 |
| Asymptotic Sig. (bilateral) | 0.563 |
Table 7 summarizes the data for the efficacy of the probiotic composition of the invention in treating AD after one month of administration, specifically as regards the variables analyzed: SCORAD index, use of topical corticosteroids and antihistamines, as compared to the placebo group.
Table 7. SCORAD index, total days of corticosteroid use and total days of antihistamine use in the group treated with the probiotic composition of the invention compared to the placebo group.
| Treatment | Mean range | Sum of ranges | Statistical significance | |
| SCORAD 1 month | Placebo | 26.28 | 525.50 | 0.016 |
| Composition | 17.16 | 377.50 | ||
| % improvement SCORAD 1 month | Placebo | 14.45 | 289.00 | 0.000 |
| Composition | 27.91 | 614.00 | ||
| V3 Total Corticosteroids | Placebo | 21.02 | 441.50 | 0.608 |
| Composition | 22.93 | 504.50 | ||
| V3 Total Antihistamines | Placebo | 22.50 | 472.50 | 0.563 |
| Composition | 21.52 | 473.50 |
A multiple linear régression analysis was performed to assess the independent effect of treatment with the probiotic composition of the invention compared to other variables that may influence the SCORAD. In this analysis the SCORAD variable is entered as the dépendent variable. In addition to the variable type of treatment, the following variables were included: total number of days of antihistamine treatment, total number of days of corticosteroid treatment and
SCORAD at baseline of the clinical trial.
One month after treatment the only variable significantly associated with the SCORAD index is the type of treatment. Accordingly, the group assigned treatment with the probiotic composition of the invention is related to an absolute decrease in the SCORAD of 9.07 points. That is, of the total decrease in SCORAD observed in the group treated with the probiotic composition of the invention during the first month, the composition of the invention is responsible for sixty-six percent (66%) of this change (9.07 out of 13.69 SCORAD points). Neither the variable for total days of antihistamine treatment or total days of corticosteroid treatment is associated with the SCORAD index.
Furthermore, systemic corticosteroid consumption was evaluated in the same way as described for topical corticosteroids consumption, as pre-specified secondary variable. The results obtained for systemic corticosteroid consumption did not show significant différences related to the use of these compounds between the two treatment groups: composition of the invention versus placebo.
Patients enrolled in the trial indicated that they suffered minor adverse effects such as flatulence in the first five days of treatment: thirty percent (30%) of the patients taking the composition of the invention versus fourteen percent (14%) in the placebo group.
In conclusion, in this example the results show that the administration of the probiotic composition of the invention for treating AD provides advantages in terms of efficacy and tolerability as compared to results for patients treated with the placebo. Thus, the parameters analyzed show a significant improvement in the SCORAD index in AD patients treated with the probiotic composition of the invention versus the placebo-treated patient group. This improvement can be observed from the first month of intake of the probiotic composition of the invention, with this improvement being maintained or increased in further analyses at months 2 and 3 of treatment.
Furthermore, regarding the total number of days that patients in each group had to use topical corticosteroids, although the mean is slightly higher in the group taking the probiotic composition ofthe invention compared to the placebo group (3.3% vs 2.6%), this différence is not significant. Conversely, on analyzing corticoids consumption at the intra-subject or intra-group level (comparing corticosteroid use at baseline and at the end of the study within the same group), a time-course trend of lower steroids consumption is observed in the group taking the probiotic composition of the invention (steroids consumption decreases by fifty-five percent (55%) as compared to the placebo group (eight percent (8%) decrease during the follow-up period), reaching statistical significance in this case.
EXAMPLE 3: Analysis of the effects of the use of the probiotic composition ofthe invention in preventing AD outbreaks.
Of the twenty (20) AD patients enrolled in the study, an intérim analysis was performed of those reaching a SCORAD index of 6. This patient group was subjected to spécifie monitoring until completing the full three-month treatment period. Ten (10) patients received placebo (Figure 11, black line) and nine (9) patients received probiotic (Figure 11, gray line).
Figure 11 shows the results for monitoring the number of AD outbreaks in ail these patients from the moment of completing the 3-month treatment with the probiotic up until 12 weeks after treatment completion. Thus, Figure 11 shows the trend in the number of patients suffering from a new AD outbreak (Figure 11 A), the total number of patients with new AD outbreaks (Figure 11 B), and the percentage of patients free from new outbreaks (Figure 11C); Considering ail previously treated patients, Figure 11 shows that the number of outbreaks, number of patients and percentage of patients suffering new AD outbreaks in the 12-week treatment-free period, is higher among those who had previously received placebo than among those who had previously received the probiotic.
Thus, in this subset of patients, those treated with the probiotic composition of the invention showed a lower relapse and/or détérioration rate than the group treated with the placebo (1 out of 10 (10%) vs 5 out of 9 (55%)), respectively (Figure 11 B).
The différences between the two intervention groups are statistically significant in the three-month évaluation period after monitoring began, for the three variables analyzed.
The data supporting the efficacy of the probiotic in terms of preventing the occurrence of new AD outbreaks are: in the three months after discontinuing treatment with the abovementioned probiotic composition, individuals who had been treated with said composition had fewer outbreaks and, therefore, a longer time period free of disease than those patients who had not received treatment.
These results demonstrate that the use of the composition of the invention is effective in preventing new outbreaks of AD. Thus, in the three months following discontinuation of treatment with the probiotic composition of the invention, patients who had been treated with said composition had fewer disease outbreaks and therefore a longer disease-free period than patients who had received the placebo.
Claims (15)
1. Probiotic composition comprising Bifidobacterium animalis subsp. lactis (B. lactis), Bifidobacterium longum and Lactobacillus casei.
2. Probiotic composition according to claim 1, wherein B. lactis is B. lactis CECT 8145, and/or B. longum is B. longum CECT 7347 and/or L. casei is L. casei CECT 9104.
3. Probiotic composition according to claim 1 or 2, wherein the probiotic composition is a pharmaceutical composition or a nutritional composition.
4. Probiotic composition according to claim 3, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and/or an excipient.
5. Probiotic composition according to claim 3 or 4, wherein the pharmaceutical composition is formulated for administration in liquid form or in solid form.
6. Probiotic composition according to claim 5, wherein the solid formulation is selected from the group consisting of tablets, lozenges, sweets, chewable tablets, chewing gum, capsules, sachets, powders, granules, coated particles or coated tablets, tablets and gastro-résistant tablets and capsules and dispersible strips and/or films.
7. Probiotic composition according to claim 5, wherein the liquid formulation is selected from the group consisting of oral solutions, suspensions, émulsions and syrups.
8. Probiotic composition according to claim 3, wherein the nutritional composition is a food or a nutritional supplément.
9. Probiotic composition according to claim 8, wherein the food is selected from the group consisting of fruit or vegetable juices, ice cream, infant formula, milk, yogurt, cheese, fermented milk, milk powder, cereals, baked goods, milk-based products, méat products and beverages.
10. Probiotic composition according to any of claims 1 to 9, wherein the composition further comprises a microorganism selected from the group consisting of Lactobacillus sp., Streptococcus sp., Bifidobacterium sp., Saccharomyces sp., Kluyveromyces sp. and combinations thereof.
11. Probiotic composition according to any of claims 1 to 10, wherein the total concentration of microorganisms of the strains B. lactis, L. casei and B. longum in the composition is between 103 and 1012 cfu, preferably 109 cfu.
12. Probiotic composition according to any of claims 1 to 11, wherein B. longum concentration is at least between 30% and 40% with respect to the total concentration of microorganisms présent in the composition; and/or B. lactis concentration is at least between 30% and 40% with respect to the total concentration of microorganisms; and/or L. casei concentration is at least between 25 and 35% with respect to the total concentration of microorganisms.
13. Probiotic composition according to claim 12, wherein B. longum concentration is 35% with respect to the total concentration of microorganisms présent in the composition; B. lactis concentration is 35% with respect to the total concentration of microorganisms, and/or L. casei concentration is 30% with respect to the total concentration of microorganisms.
14. Probiotic composition according to any of claims 1 to 13 for use as a drug.
15. Probiotic composition according to any of claims 1 to 13 for use in the treatment and / or prévention of atopie dermatitis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382342.0 | 2016-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA19179A true OA19179A (en) | 2020-03-09 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230048705A1 (en) | Use of probiotics in the treatment and/or prevention of atopic dermatitis | |
| EP3432899B1 (en) | Use of probiotics in the treatment and/or prevention of psoriasis | |
| Serce et al. | Efficacy of Saccharomyces boulardii on necrotizing enterocolitis or sepsis in very low birth weight infants: a randomised controlled trial | |
| EP3442547B1 (en) | Lactobacillus reuteri mm4-1a for use in the treatment or prevention of autism spectrum disorders | |
| EP4048299B1 (en) | Probiotic composition for use as an antioxidant | |
| Pande et al. | Prospectus of probiotics in modern age diseases | |
| US20240307465A1 (en) | Methods of preventing, delaying or ameliorating atopic diseases | |
| Wibowo et al. | The status of probiotics supplementation during pregnancy | |
| OA19179A (en) | Use of probiotics in the treatment and/or prevention of atopic dermatitis. | |
| EA040422B1 (en) | THE USE OF PROBIOTICS IN THE TREATMENT AND/OR PREVENTION OF ADOPIC DERMATITIS | |
| OA18880A (en) | Use of probiotics in the treatment and/or prevention of psoriasis |